Market Wire (Free subscription) | 30/09/2008
MECHELEN, BELGIUM (MARKET WIRE) Galapagos NV (Euronext: GLPG) announced today that it has received a transparency notification from Delta Lloyd, disclosing that they hold a 5.4% interest in the share capital of Galapagos.
Market Wire - Medical and Healthcare: Healthcare (Free subscription) | 15/09/2008
MECHELEN, BELGIUM (MARKET WIRE)
Fiercebiotech (Free subscription) | 26/08/2008
Belgium's Galapagos NV has bought out Sareum's assets in drug discovery services for 695,000 euros. The assets will help position Galapagos' service division, BioFocus DPI, in the structure-based drug discovery field. In structure-based drug design, the three-dimensional structure of a drug target is used to guide the discovery of small molecules. "We are pleased to have acquired Sareum's structure-based...
Market Wire (Free subscription) | 12/08/2008
MECHELEN, BELGIUM (MARKET WIRE)
Market Wire (Free subscription) | 08/08/2008
MECHELEN, BELGIUM (MARKET WIRE)
Market Wire (Free subscription) | 23/07/2008
MECHELEN, BELGIUM (MARKET WIRE)
Market Wire - Medical and Healthcare: Healthcare (Free subscription) | 22/07/2008
MECHELEN, BELGIUM (MARKET WIRE)
Red Orbit (Free subscription) | 18/07/2008
Mechelen, Belgium; 18 July 2008 - Galapagos NV (Euronext: GLPG) announced today that it has reached the first milestone in its osteoporosis collaboration with Eli Lilly and Company (NYSE: LLY), triggering a payment of EUR 1 million from Lilly.
Market Wire (Free subscription) | 18/07/2008
MECHELEN, BELGIUM (MARKET WIRE)
Market Wire (Free subscription) | 17/07/2008
MECHELEN, BELGIUM (MARKET WIRE)
Market Wire - Medical and Healthcare: Healthcare (Free subscription) | 02/07/2008
MECHELEN, BELGIUM (MARKET WIRE) Galapagos NV (Euronext: GLPG) announced today that its Board of Directors on 26 June 2008 has created and offered 250,065 warrants under a new warrant plan for Galapagos employees and consultants. Furthermore, the Extraordinary General Shareholders' Meeting (EGM) held on 26 June 2008 approved the offer of 57,500 warrants for the benefit of directors of the company.
Contract Pharma Breaking News (Free subscription) | 30/06/2008
Galapagos NV's service division, BioFocus DPI , will provide compound management and related services to Sepracor for a total contract value of $1.5 million. Under the terms of the agreement, BioFocus DPI will receive, register, and store selected compounds from Sepracor's compound library, and plate and replicate these compounds for three years. Services will be provided by BioFocus DPI's compound...
Red Orbit (Free subscription) | 16/06/2008
Mechelen, Belgium; 16 June 2008 - Galapagos NV (Euronext: GLPG) announced today that it has reached two new milestones in its multi-year drug discovery alliance with GlaxoSmithKline in osteoarthritis, triggering a payment of EUR 0.8 million from GSK.
Market Wire (Free subscription) | 03/06/2008
MECHELEN, BELGIUM (MARKET WIRE)
Market Wire (Free subscription) | 19/05/2008
MECHELEN, BELGIUM (MARKET WIRE)
